Alimera Sciences Inc. Daily Stock Analysis

Daily Stock Analysis, ALIM, Alimera Sciences Inc, priceseries

Alimera Sciences Inc. Daily Stock Analysis
Stock Information
Open
4.84
Close
4.66
High
4.96
Low
4.66
Previous Close
4.79
Daily Price Gain
-0.13
YTD High
5.48
YTD High Date
Jan 3, 2022
YTD Low
4.01
YTD Low Date
Jan 27, 2022
YTD Price Change
-0.31
YTD Gain
-6.24%
52 Week High
12.25
52 Week High Date
Mar 19, 2021
52 Week Low
3.94
52 Week Low Date
Oct 12, 2021
52 Week Price Change
-2.87
52 Week Gain
-38.11%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Mar 8. 2017
19.65
Mar 20. 2017
22.38
8 Trading Days
13.92%
Link
LONG
Jun 26. 2018
13.52
Jul 26. 2018
16.23
21 Trading Days
20.06%
Link
LONG
Aug 21. 2018
13.88
Sep 19. 2018
15.97
20 Trading Days
15.06%
Link
LONG
Sep 18. 2019
6.33
Oct 1. 2019
7.16
9 Trading Days
13.04%
Link
LONG
Nov 25. 2019
4.87
Dec 16. 2019
7.58
14 Trading Days
55.72%
Link
LONG
Feb 20. 2020
6.57
Feb 25. 2020
6.91
3 Trading Days
5.18%
Link
LONG
Jun 16. 2020
5.18
Jun 29. 2020
6.19
9 Trading Days
19.43%
Link
LONG
Jan 5. 2021
4.52
Jan 27. 2021
7.24
15 Trading Days
60.14%
Link
LONG
Feb 3. 2021
7.08
Feb 22. 2021
8.70
12 Trading Days
22.81%
Link
LONG
Mar 10. 2021
9.27
Mar 22. 2021
10.40
8 Trading Days
12.23%
Link
LONG
Apr 13. 2021
10.32
Apr 15. 2021
10.88
2 Trading Days
5.47%
Link
LONG
May 20. 2021
9.50
Jun 8. 2021
10.11
12 Trading Days
6.47%
Link
LONG
Nov 3. 2021
4.44
Nov 16. 2021
5.61
9 Trading Days
26.39%
Link
Company Information
Stock Symbol
ALIM
Exchange
NasdaqGM
Company URL
http://www.alimerasciences.com
Company Phone
6789905740
CEO
Charles Daniel Myers
Headquarters
Georgia
Business Address
6120 WINDWARD PARKWAY, STE 290, ALPHARETTA, GA 30005
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0001267602
About

Alimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the U.S. and International geographic segments. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration, and retinal vein occlusion. Its portfolio includes ILUVIEN and NADPH Oxidase Inhibitors. The company was founded on June 4, 2003 by Daniel C. Myers and David R. Holland and is headquartered in Alpharetta, GA.

Description

Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-sealing wound by delivering a continuous microdose of the non-proprietary corticosteroid fluocinolone acetonide in the eye. The company has an agreement with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans other than uveitis or to treat DME. Alimera Sciences, Inc. was founded in 2003 and is headquartered in Alpharetta, Georgia.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading